Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 12, 2015, Pages 3776-3781

  Mandelin, Jami ^a,e   Cardó Vila, Marina ^b,c   Driessen, Wouter H P ^a,f   Mathew, Paul ^a,g   Navonea, Nora M ^a   Lin, Sue Hwa ^a   Logothetis, Christopher J ^a   Rietz, Anna Cecilia ^b,c   Dobroff, Andrey S ^b,c   Proneth, Bettina ^a,h   L Sidman, Richard ^d   Pasqualini, Renata ^b,c   Arap, Wadih ^b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF HELSINKI   (Finland)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g TUFTS MEDICAL CENTER   (United States)

^h INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

GRP78; Ligand receptors; Peptides; Phage display; Tumor targeting

Indexed keywords

ALPHA 2 MACROGLOBULIN; CERULOPLASMIN; FIBULIN; GLUCOSE REGULATED PROTEIN 78; HEAT SHOCK COGNATE PROTEIN 70; LIGAND; PEPTIDE DERIVATIVE; PROLYLLYSYLARGINYLGLYCYLPHENYLALANYLGLUTAMINYLASPARTIC ACID; SERYLASPARAGINYLTHREONYLARGINYLVALYLALANYLPROLINE; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR; HEAT SHOCK PROTEIN; MOLECULAR CHAPERONE GRP78; PEPTIDE; PROTEIN BINDING;

ADULT; AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIOPHAGE; CASTRATE RESISTANT OSTEOGENIC PROSTATE CANCER; CASTRATION RESISTANT PROSTATE CANCER; CELL SURFACE; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; MASS SPECTROMETRY; MIDDLE AGED; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PEPTIDE LIBRARY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN TARGETING; WESTERN BLOTTING; ANIMAL; BONE DEVELOPMENT; BONE TUMOR; CANCER TRANSPLANTATION; CHEMISTRY; DISEASE COURSE; DRUG DESIGN; DRUG SCREENING; METABOLISM; NANOTECHNOLOGY; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEOMICS; SCID MOUSE; SECONDARY; TUMOR CELL LINE;

ALPHA-MACROGLOBULINS; ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CHROMATOGRAPHY, AFFINITY; DISEASE PROGRESSION; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HEAT-SHOCK PROTEINS; HUMANS; LIGANDS; MALE; MICE; MICE, SCID; NANOTECHNOLOGY; NEOPLASM TRANSPLANTATION; OSTEOGENESIS; PEPTIDES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN BINDING; PROTEOMICS; RECEPTORS, ANDROGEN;

EID: 84925637671     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1500128112     Document Type: Article

References (59)

1. Hadaschik BA, Sowery RD, Gleave ME (2007) Novel targets and approaches in advanced prostate cancer. Curr Opin Urol 17(3):182-187.
2. Logothetis CJ, Lin SH (2005) Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5(1):21-28.
3. Corey E, et al. (2002) Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 52(1):20-33.
4. Lee YP, et al. (2002) Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 62(19):5564-5570.
5. Thalmann GN, et al. (2000) LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis. Prostate 44(2):91-103.
6. Yang J, et al. (2001) Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 61(14):5652-5659.
7. Li ZG, et al. (2008) Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 118(8):2697-2710.
8. Pasqualini R, Ruoslahti E (1996) Organ targeting in vivo using phage display peptide libraries. Nature 380(6572):364-366.
9. Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279(5349):377-380.
10. Ellerby HM, et al. (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5(9):1032-1038.
11. Arap W, et al. (2002) Steps toward mapping the human vasculature by phage display. Nat Med 8(2):121-127.
12. Arap W, et al. (2002) Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA 99(3):1527-1531.
13. Kolonin MG, et al. (2006) Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J 20(7):979-981.
14. Yao VJ, et al. (2005) Targeting pancreatic islets with phage display assisted by laser pressure catapult microdissection. Am J Pathol 166(2):625-636.
15. Arap MA, et al. (2004) Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell 6(3):275-284.
16. Hajitou A, et al. (2006) A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 125(2):385-398.
17. Pasqualini R, Koivunen E, Ruoslahti E (1997) Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 15(6):542-546.
18. Kim Y, et al. (2006) Targeting heat shock proteins on cancer cells: Selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry 45(31):9434-9444.
19. Mintz PJ, et al. (2003) Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 21(1):57-63.
20. Scher HI, et al. (2005) Cancer of the prostate. Cancer Principles and Practise of Oncology, eds DeVita VT, Jr, Hellman S, Rosenberg SA (Lippincott Williams & Wilkins, Philadelphia), 7th Ed.
21. Lauer RC, Friend SC, Rietz C, Pasqualini R, Arap W (2015) Drug design strategies for the treatment of prostate cancer. Expert Opin Drug Discov 10(1):81-90.
22. Clinton GM, et al. (1996) Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc Natl Acad Sci USA 93(1):316-320.
23. Gu YC, Nilsson K, Eng H, Ekblom M (2000) Association of extracellular matrix proteins fibulin-1 and fibulin-2 with fibronectin in bone marrow stroma. Br J Haematol 109(2):305-313.
24. Pupa SM, et al. (2007) Regulation of breast cancer response to chemotherapy by fibulin-1. Cancer Res 67(9):4271-4277.
25. Wlazlinski A, et al. (2007) Downregulation of several fibulin genes in prostate cancer. Prostate 67(16):1770-1780.
26. Ziche M, Jones J, Gullino PM (1982) Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst 69(2):475-482.
27. Green JA, Pocklington T, Dawson AA, Foster M (1980) Electron spin resonance studies on caeruloplasmin and iron transferrin in patients with chronic lymphocytic leukaemia. Br J Cancer 41(3):356-359.
28. Lamoureux G, Mandeville R, Poisson R, Legault-Poisson S, Jolicoeur R (1982) Biologic markers and breast cancer: A multiparametric study - 1. Increased serum protein levels. Cancer 49(3):502-512.
29. Shifrine M, Fisher GL (1976) Ceruloplasmin levels in sera from human patients with osteosarcoma. Cancer 38(1):244-248.
30. Fotiou K, et al. (2007) Serum ceruloplasmin as a marker in prostate cancer. Minerva Urol Nefrol 59(4):407-411.
31. Nayak SB, Bhat VR, Upadhyay D, Udupa SL (2003) Copper and ceruloplasmin status in serum of prostate and colon cancer patients. Indian J Physiol Pharmacol 47(1):108-110.
32. Briggs MH (1978-1979) Biochemical basis for the selection of oral contraceptives. Int J Gynaecol Obstet 16(6):509-517.
33. Doe RP, Mellinger GT, Swaim WR, Seal US (1967) Estrogen dosage effects on serum proteins: A longitudinal study. J Clin Endocrinol 27:1081-1086.
34. Henry NL, et al. (2006) Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. Oncology 71(3-4):168-175.
35. Borth W (1992) Alpha 2-macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J 6(15):3345-3353.
36. Misra UK, Deedwania R, Pizzo SV (2006) Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78. J Biol Chem 281(19):13694-13707.
37. 2-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells. PLoS ONE 7(12):e51735.
38. Sinnreich O, et al. (2004) Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: Association to clinicopathological parameters. Prostate 61(3):201-208.
39. Jolly C, Morimoto RI (2000) Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 92(19):1564-1572.
40. King LS, et al. (2001) Isolation, expression, and characterization of fully functional nontoxic BiP/GRP78 mutants. Protein Expr Purif 22(1):148-158.
41. Lee AS (2007) GRP78 induction in cancer: Therapeutic and prognostic implications. Cancer Res 67(8):3496-3499.
42. Luo S, Baumeister P, Yang S, Abcouwer SF, Lee AS (2003) Induction of Grp78/BiP by translational block: Activation of the Grp78 promoter by ATF4 through and upstream ATF/CRE site independent of the endoplasmic reticulum stress elements. J Biol Chem 278(39):37375-37385.
43. Luo S, Mao C, Lee B, Lee AS (2006) GRP78/BiP is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development. Mol Cell Biol 26(15):5688-5697.
44. Wooden SK, Lee AS (1992) Comparison of the genomic organizations of the rat grp78 and hsc73 gene and their evolutionary implications. DNA Seq 3(1):41-48.
45. Davidson DJ, et al. (2005) Kringle 5 of human plasminogen induces apoptosis of endothelial and tumor cells through surface-expressed glucose-regulated protein 78. Cancer Res 65(11):4663-4672.
46. Delpino A, Piselli P, Vismara D, Vendetti S, Colizzi V (1998) Cell surface localization of the 78 kD glucose regulated protein (GRP 78) induced by thapsigargin. Mol Membr Biol 15(1):21-26.
47. Gonzalez-Gronow M, et al. (2006) Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. Cancer Res 66(23):11424-11431.
48. Shani G, et al. (2008) GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth. Mol Cell Biol 28(2):666-677.
49. Takemoto H, et al. (1992) Heavy chain binding protein (BiP/GRP78) and endoplasmin are exported from the endoplasmic reticulum in rat exocrine pancreatic cells, similar to protein disulfide-isomerase. Arch Biochem Biophys 296(1):129-136.
50. Triantafilou M, Fradelizi D, Triantafilou K (2001) Major histocompatibility class one molecule associates with glucose regulated protein (GRP) 78 on the cell surface. Hum Immunol 62(8):764-770.
51. Xiao G, Chung TF, Pyun HY, Fine RE, Johnson RJ (1999) KDEL proteins are found on the surface of NG108-15 cells. Brain Res Mol Brain Res 72(2):121-128.
52. Sokolowska I, Woods AG, Gawinowicz MA, Roy U, Darie CC (2012) Identification of a potential tumor differentiation factor receptor candidate in prostate cancer cells. FEBS J 279(14):2579-2594.
53. Liu R, et al. (2013) Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis. Clin Cancer Res 19(24):6802-6811.
54. Lee AS (2014) Glucose-regulated proteins in cancer: Molecular mechanisms and therapeutic potential. Nat Rev Cancer 14(4):263-276.
55. Rasche L, et al. (2013) The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78. PLoS ONE 8(5):e63414.
56. Rauschert N, et al. (2008) A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab Invest 88(4):375-386.
57. Daneshmand S, et al. (2007) Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol 38(10):1547-1552.
58. Pootrakul L, et al. (2006) Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin Cancer Res 12(20 Pt 1):5987-5993.
59. Roller C, Maddalo D (2013) The molecular chaperone GRP78/BiP in the development of chemoresistance: Mechanism and possible treatment. Front Pharmacol 4:10.